AstraZeneca Pharma India Ltd. - Research Center
506820 ASTRAZEN Group (A) BSE data
Add to watchlist
| Results |
Half yearly
|
| Statement | |
| More |
Half yearly results in brief
(Rs crore)
| Sep ' 23 | Sep ' 22 | Mar ' 22 | Sep ' 21 | Sep ' 20 | |
|---|---|---|---|---|---|
| Sales | 606.54 | 468.46 | 432.49 | 373.11 | 403.05 |
| Operating profit | 120.00 | 68.69 | 52.63 | 33.55 | 64.33 |
| Interest | 0.65 | 0.35 | 0.44 | 0.51 | 0.55 |
| Gross profit | 135.83 | 79.25 | 61.21 | 38.78 | 71.14 |
| EPS (Rs) | 42.49 | 21.09 | 15.76 | 8.88 | 17.99 |
Half yearly
results in details
| Sep ' 23 | Sep ' 22 | Mar ' 22 | Sep ' 21 | Sep ' 20 | |
|---|---|---|---|---|---|
| Other income | 16.48 | 10.91 | 9.01 | 5.74 | 7.36 |
| Stock adjustment | -67.96 | -12.28 | 15.53 | -1.06 | -11.12 |
| Raw material | 57.88 | 35.65 | 49.30 | 40.31 | 44.83 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 120.24 | 129.56 | 117.73 | 112.48 | 111.99 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | -20.12 | 20.12 | 20.73 |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 376.37 | 246.83 | 217.43 | 167.71 | 172.30 |
| Provisions made | - | - | - | - | - |
| Depreciation | 7.47 | 7.88 | 7.91 | 9.04 | 9.18 |
| Taxation | 38.55 | 18.65 | 13.89 | 7.55 | 16.98 |
| Net profit / loss | 106.23 | 52.72 | 39.40 | 22.19 | 44.97 |
| Extra ordinary item | 16.43 | - | - | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 19.79 | 14.66 | 12.17 | 8.99 | 15.96 |
| GPM (%) | 21.80 | 16.53 | 13.86 | 10.24 | 17.33 |
| NPM (%) | 17.05 | 11.00 | 8.92 | 5.86 | 10.96 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis